University of Wolverhampton
Browse
Collection All
bullet
bullet
bullet
bullet
Listed communities
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

Wolverhampton Intellectual Repository and E-Theses > Research Institutes > Research Institute in Healthcare Science > Molecular Pharmacology Research Group > Bradykinin receptors as a therapeutic target

Please use this identifier to cite or link to this item: http://hdl.handle.net/2436/29935
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!



Title: Bradykinin receptors as a therapeutic target
Authors: Howl, John D.
Payne, Sarah J.
Citation: Expert Opinion on Therapeutic Targets, 7(2): 277-85
Publisher: London: Informa Healthcare
Journal: Expert Opinion on Therapeutic Targets
Issue Date: 2003
URI: http://hdl.handle.net/2436/29935
DOI: 10.1517/14728222.7.2.277
PubMed ID: 12667103
Additional Links: http://www.expertopin.com/doi/abs/10.1517/14728222.7.2.277
Abstract: Biologically-active kinins, including bradykinin (BK) and Lys(0)-BK (kallidin), are short-lived peptide mediators predominantly generated by the enzymatic action of kallikreins on kininogen precursors. A diverse spectrum of physiological and pathological actions attributed to local kinin production is a consequence of the activation of G-protein-coupled receptors (GPCRs). Currently, two major subtypes of kinin receptor, designated B(1) and B(2), are recognised, although there is much evidence for pharmacological heterogeneity, particularly within the B(2) receptors. Considering these facts and the widespread distribution of kinin receptors in many human tissues, it is no surprise that the therapeutic potential of kinins and kinin receptor antagonists remains the focus of numerous investigations. Studies in animals and animal tissues, instrumental in elucidating the biological roles of kinins, are well-documented in numerous excellent reviews. Unfortunately, and despite the enormous potential illustrated by animal studies, attempts to develop kinin analogues as therapeutic agents to combat human disease have largely proven disappointing. Consequently, this review selectively focuses upon studies that are directly relevant to the targeting of human BK receptors as a therapeutic intervention. In addition to providing a succinct review of well-documented pathological conditions to which kinin receptors contribute, the authors have also included more recent data that illustrate new avenues for the therapeutic application of kinin analogues.
Type: Article
Language: en
Keywords: Peptides
Therapeutics
MeSH: Analgesics
Anti-Inflammatory Agents
Bradykinin
Cardiovascular System
Drug Design
Humans
Inflammation
Kallikreins
Kininogens
Kinins
Pain
Receptors, Bradykinin
Signal Transduction
ISSN: 1744-7631
Appears in Collections: Molecular Pharmacology Research Group

Files in This Item:

There are no files associated with this item.



Related articles on PubMed
bullet
Kinins and kinin receptors in the nervous system.
Walker K, Perkins M, Dray A
1995 Jan
bullet
bullet
bullet
bullet
See all 282 articles

All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Fairtrade - Guarantees a better deal for Third World Producers

University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1LY

Course enquiries: 0800 953 3222, General enquiries: 01902 321000,
Email: enquiries@wlv.ac.uk | Freedom of Information | Disclaimer and copyright | Website feedback | The University as a charity

OR Logo Powered by Open Repository | Cookies